Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next year, its CEO said on Tuesday, the latest Chinese company to join the race ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...